| 2021 |
Teguh DA, Nustad JL, Craven AE, Brooks DJ, Arlt H, Hu D, Baron R, Lanske B, Bouxsein ML. Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading. Bone. March 2021;144:115801. |
1 |
1 |
| 2020 |
Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer J-P, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH. Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim/oim mice. Calcif Tiss Int. May 2020;106(5):494-508. |
2 |
2 |
| 2016 |
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu M-y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. August 16, 2016;316(7):722-733. |
42 |
35 |
| 2017 |
Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, Balani DH, Ominsky MS, Ke HZ, Kronenberg HM, Wein MN. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J Bone Miner Res. May 2017;32(5):892-901. |
16 |
14 |
| 2021 |
Eastell R, Black DM, Lui L, Chines A, Marin F, Khosla S, de Papp AE, Cauley JA, Mitlak B, McCulloch CE, Vittinghoff E, Bauer DC; Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment‐related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. J Bone Miner Res. February 2021;36(2):236-243. |
0 |
0 |
| 2021 |
Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH. Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res. April 2021;36(4):644-653. |
4 |
3 |
| 2022 |
Eastell R, Vittinghoff E, Lui L-Y, McCulloch CE, Pavo I, Chines A, Khosla S, Cauley JA, Mitlak B, Bauer DC, Bouxsein M, Black DM. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res. January 2022;37(1):29-35. |
5 |
3 |
| 2022 |
Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, Binkley N, Lewiecki EM, Adachi J, Knychas D, Kendler D, Orwoll E, Chen Y, Pearman L, Li YH, Mitlak B. The efficacy and safety of abaloparatide-sc in men with osteoporosis: a randomized clinical trial. J Bone Miner Res. December 2022;37(12):2435-2442. |
0 |
0 |
| 2023 |
Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B. Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVExtend. J Bone Miner Res. April 2023;38(4):464-470. |
0 |
0 |
| 2023 |
Lewiecki EM, Czerwinski E, Recknor C, Strzelecka A, Valenzuela G, Lawrence M, Silverman S, Cardona J, Nattrass SM, Binkley N, Annett M, Pearman L, Mitlak B. Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study. J Bone Miner Res. October 2023;38(10):1404-1414. |
1 |
1 |
| 2020 |
Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F. Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. May 2020;31(5):1017-1018. |
1 |
1 |
| 2020 |
Lewiecki EM, Chastek B, Sundquist K, Williams SA, Weiss RJ, Wang Y, Fitzpatrick LA, Curtis JR. Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. Osteoporos Int. July 2020;31(7):1299-1304. |
2 |
2 |
| 2020 |
Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F. Correction to: abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. August 2020;31(8):1603-1605. |
0 |
0 |
| 2020 |
Imel EA, Starzyk K, Gliklich R, Weiss RJ, Wang Y, Williams SA. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis. Osteoporos Int. December 2020;31(12):2413-2424. |
0 |
0 |
| 2021 |
Watts NB, Dore RK, Baim S, Mitlak B, Hattersley G, Wang Y, Rozental TD, LeBoff MS. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. Osteoporos Int. January 2021;32(1):55-61. |
0 |
0 |
| 2021 |
Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ. Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int. March 2021;32(3):575-583. |
2 |
0 |